Analysed NURIX THERAPEUTICS INC (NRIX:NASDAQ) News Sources
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
30-06-2026
yahoo.com
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
01-07-2026
yahoo.com
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
09-07-2026
yahoo.com
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
21-07-2026
yahoo.com
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
04-08-2026
yahoo.com
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
10-08-2026
yahoo.com
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
20-08-2026
yahoo.com
What is the current price of NURIX THERAPEUTICS INC (NRIX:NASDAQ)?
The current price of NURIX THERAPEUTICS INC (NRIX:NASDAQ) is $25.1.
NURIX THERAPEUTICS INC (NRIX:NASDAQ) absolute price change since previous trading day?
The absolute price change of NURIX THERAPEUTICS INC (NRIX:NASDAQ) since the previous trading day is $-0.71.
NURIX THERAPEUTICS INC (NRIX:NASDAQ) percentage price change since previous trading day?
The percentage price change of NURIX THERAPEUTICS INC (NRIX:NASDAQ) since the previous trading day is -2.7509%.
What is the most recent average sentiment score for NURIX THERAPEUTICS INC (NRIX:NASDAQ)?
The most recent average sentiment score for NURIX THERAPEUTICS INC (NRIX:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for NURIX THERAPEUTICS INC (NRIX:NASDAQ)?
The most recent sentiment for NURIX THERAPEUTICS INC (NRIX:NASDAQ) is .
SEC-8K** Filing Available For NURIX THERAPEUTICS INC (NRIX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.